78 related articles for article (PubMed ID: 25301406)
1. Extended-release tacrolimus: a review of its use in de novo kidney transplantation.
McCormack PL
Drugs; 2014 Nov; 74(17):2053-64. PubMed ID: 25352392
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.
Birdwell KA; Decker B; Barbarino JM; Peterson JF; Stein CM; Sadee W; Wang D; Vinks AA; He Y; Swen JJ; Leeder JS; van Schaik R; Thummel KE; Klein TE; Caudle KE; MacPhee IA
Clin Pharmacol Ther; 2015 Jul; 98(1):19-24. PubMed ID: 25801146
[TBL] [Abstract][Full Text] [Related]
3. Choosing the right dose of tacrolimus.
Lancia P; Jacqz-Aigrain E; Zhao W
Arch Dis Child; 2015 Apr; 100(4):406-13. PubMed ID: 25416736
[TBL] [Abstract][Full Text] [Related]
4. [The genome and pharmacology].
Brøsen K; Damkier P
Ugeskr Laeger; 2014 Nov; 176(46):. PubMed ID: 25394937
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis.
Mocchegiani F; Montalti R; Nicolini D; Svegliati Baroni G; Benedetti A; Risaliti A; Vivarelli M
Ann Transplant; 2014 Oct; 19():545-50. PubMed ID: 25347718
[TBL] [Abstract][Full Text] [Related]
6. The tacrolimus metabolism rate influences renal function after kidney transplantation.
Thölking G; Fortmann C; Koch R; Gerth HU; Pabst D; Pavenstädt H; Kabar I; Hüsing A; Wolters H; Reuter S; Suwelack B
PLoS One; 2014; 9(10):e111128. PubMed ID: 25340655
[TBL] [Abstract][Full Text] [Related]
7. Effect of Multidrug-Resistant 1 (MDR1) and CYP3A4*1B Polymorphisms on Cyclosporine-Based Immunosuppressive Therapy in Renal Transplant Patients.
Kotowski MJ; Bogacz A; Bartkowiak-Wieczorek J; Tejchman K; Dziewanowski K; Ostrowski M; Czerny B; Grześkowiak E; Machaliński B; Sieńko J
Ann Transplant; 2019 Feb; 24():108-114. PubMed ID: 30799432
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
Pascual T; Apellániz-Ruiz M; Pernaut C; Cueto-Felgueroso C; Villalba P; Álvarez C; Manso L; Inglada-Pérez L; Robledo M; Rodríguez-Antona C; Ciruelos E
PLoS One; 2017; 12(7):e0180192. PubMed ID: 28727815
[TBL] [Abstract][Full Text] [Related]
9. HSD11B1 rs846908 polymorphisms and tacrolimus concentrations: quantum chemical analysis and implication in patients with renal transplantation.
Joob B; Wiwanitkit V
J Nephropharmacol; 2017; 6(1):19-20. PubMed ID: 28197525
[No Abstract] [Full Text] [Related]
10. Functional AdoMet Isosteres Resistant to Classical AdoMet Degradation Pathways.
Huber TD; Wang F; Singh S; Johnson BR; Zhang J; Sunkara M; Van Lanen SG; Morris AJ; Phillips GN; Thorson JS
ACS Chem Biol; 2016 Sep; 11(9):2484-91. PubMed ID: 27351335
[TBL] [Abstract][Full Text] [Related]
11. Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis.
Shi WL; Tang HL; Zhai SD
PLoS One; 2015; 10(6):e0127995. PubMed ID: 26039043
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of immunosuppressants: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics (RNPGx).
Woillard JB; Chouchana L; Picard N; Loriot MA;
Therapie; 2017 Apr; 72(2):285-299. PubMed ID: 28318610
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs.
Picard N; Bergan S; Marquet P; van Gelder T; Wallemacq P; Hesselink DA; Haufroid V
Ther Drug Monit; 2016 Apr; 38 Suppl 1():S57-69. PubMed ID: 26469711
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.
McCune JS; Bemer MJ
Clin Pharmacokinet; 2016 May; 55(5):525-50. PubMed ID: 26563168
[TBL] [Abstract][Full Text] [Related]
15. Thiopurine S-methyltransferase polymorphism in Iranian kidney transplant recipients.
Aghdaie MH; Azarpira N; Geramizadeh B; Sagheb M; Darai M; Rahsaz M; Malekhoseini SA
Exp Clin Transplant; 2011 Aug; 9(4):241-6. PubMed ID: 21819368
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics and immunosuppressive drugs.
Hronová K; Šíma M; Světlík S; Matoušková O; Slanař O
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):821-35. PubMed ID: 25301406
[TBL] [Abstract][Full Text] [Related]
17. Use of pharmacogenetics to optimize immunosuppressive therapy.
Macphee IA
Ther Drug Monit; 2010 Jun; 32(3):261-4. PubMed ID: 20431509
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
